Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Vladimir Zah, Rowe B Brookfield, Martina Imro, Simona Tatovic, Jovana Pelivanovic & Djurdja Vukicevic. (2019) Healthcare Costs And Resource Utilization In Chronic Pain Patients Treated With Extended-Release Formulations Of Tapentadol, Oxycodone, Or Morphine Stratified By Type Of Pain: A Retrospective Claims Analysis, 2012–2016. Journal of Pain Research 12, pages 3037-3048.
Read now
Read now
Lorenzo Panella, Giuseppe Rinonapoli & Stefano Coaccioli. (2019) Where should analgesia lead to? Quality of life and functional recovery with tapentadol. Journal of Pain Research 12, pages 1561-1567.
Read now
Read now
Wojciech Leppert, Renata Zajaczkowska & Jerzy Wordliczek. (2019) The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation. Expert Opinion on Pharmacotherapy 20:5, pages 511-522.
Read now
Read now
Michael A Ueberall & Gerhard H H Mueller-Schwefe. (2016) Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations. Journal of Pain Research 9, pages 1001-1020.
Read now
Read now
Ron Goeree & Jeff Goeree. (2016) Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada. Journal of Medical Economics 19:3, pages 277-291.
Read now
Read now
Nalini Vadivelu, Alice Kai, Benjamin Maslin, Gopal Kodumudi, Aron Legler & Jack M Berger. (2015) Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Therapeutics and Clinical Risk Management 11, pages 95-105.
Read now
Read now
Flaminia Coluzzi, Robert B Raffa, Joseph Pergolizzi, Alessandra Rocco, Pamela Locarini, Natalia Cenfra, Giuseppe Cimino & Consalvo Mattia. (2015) Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. Journal of Pain Research 8, pages 229-238.
Read now
Read now
Wojciech Leppert. (2015) Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction. Drug Design, Development and Therapy 9, pages 2215-2231.
Read now
Read now
Carmelo Scarpignato & Luigi Gatta. (2015) Comparing tapentadol to oxycodone/naloxone combination: building castles in the air. Current Medical Research and Opinion 31:2, pages 335-338.
Read now
Read now
J.D. Belsey. (2015) Appropriate use of information in therapeutic decision-making: reflections on indirect comparisons. Current Medical Research and Opinion 31:2, pages 343-346.
Read now
Read now
Articles from other publishers (20)
Arturo Cuomo, Franco Marinangeli, Alberto Magni, Emiliano Petrucci, Alessandro Vittori & Marco Cascella. (2023) Investigating Functional Impairment in Chronic Low Back Pain: A Qualitative Study from the Patients and Specialists’ Perspectives. Journal of Personalized Medicine 13:6, pages 1012.
Crossref
Crossref
Stephanie C Ternel (Lebret). (2023) Considerations for perioperative opioid analgesic stewardship in Australia: a focus on tapentadol. Pain Management 13:5, pages 299-307.
Crossref
Crossref
Fengyao Mei, Jiao Jiao Li, Jiarong Li, Shengjie Dong, Zhichang Li & Dan Xing. (2022) Global Cluster Analysis and Network Visualization in Musculoskeletal Pain Management: A Scientometric Mapping. Orthopaedic Surgery 15:1, pages 301-314.
Crossref
Crossref
Jordi Barrachina, Cesar Margarit, Javier Muriel, Santiago López-Gil, Vicente López-Gil, Amaya Vara-González, Beatriz Planelles, María-del-Mar Inda, Domingo Morales & Ana M. Peiró. (2022) Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study. Scientific Reports 12:1.
Crossref
Crossref
Flaminia Coluzzi, Laura Rullo, Maria Sole Scerpa, Loredana Maria Losapio, Monica Rocco, Domenico Billeci, Sanzio Candeletti & Patrizia Romualdi. (2022) Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation. CNS Drugs 36:6, pages 617-632.
Crossref
Crossref
Matteo Ruggeri, Alessandro Signorini, Silvia Caravaggio, Costanza Santori, Francesco Rosiello & Flaminia Coluzzi. (2021) Cost-Effectiveness Analysis of Tapentadol Versus Oxycodone/Naloxone in both Branded and Generic Formulations in Patients with Musculoskeletal Pain. Clinical Drug Investigation 41:10, pages 875-883.
Crossref
Crossref
Lucien Roulet, Victoria Rollason, Jules Desmeules & Valérie Piguet. (2021) Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients. Drugs 81:11, pages 1257-1272.
Crossref
Crossref
Donald J. Coluzzi, Zahra Al Timimi & Mohammed Saleem. 2021. Digitization in Dentistry. Digitization in Dentistry
141
167
.
Tiziana D’Amato, Federica Martorelli, Giorgia Fenocchio, Vincenzo Simili, Elizaveta Kon, Berardo Di Matteo & Marco Scardino. (2019) Tapentadol vs oxycodone/naloxone in the management of pain after total hip arthroplasty in the fast track setting: an observational study. Journal of Experimental Orthopaedics 6:1.
Crossref
Crossref
F. Coluzzi, D. Billeci, M. Maggi & G. Corona. (2018) Testosterone deficiency in non-cancer opioid-treated patients. Journal of Endocrinological Investigation 41:12, pages 1377-1388.
Crossref
Crossref
Bart J. Morlion, Stefan A. Mueller‐Lissner, Renato Vellucci, Wojciech Leppert, Benoît C. Coffin, Sara L. Dickerson & Tony O'Brien. (2017) Oral Prolonged‐Release Oxycodone/Naloxone for Managing Pain and Opioid‐Induced Constipation: A Review of the Evidence. Pain Practice 18:5, pages 647-665.
Crossref
Crossref
Esther S. Kim. (2017) Oxycodone/Naloxone Prolonged Release: A Review in Severe Chronic Pain. Clinical Drug Investigation 37:12, pages 1191-1201.
Crossref
Crossref
Edvina Galiè, Veronica Villani, Irene Terrenato & Andrea Pace. (2017) Tapentadol in neuropathic pain cancer patients: a prospective open label study. Neurological Sciences 38:10, pages 1747-1752.
Crossref
Crossref
Joseph V PergolizziJrJr, Frank Breve, Robert TaylorJrJr, Robert B Raffa, Stephani E Strasburger & Jo Ann LeQuang. (2017) Considering tapentadol as a first-line analgesic: 14 questions. Pain Management 7:4, pages 331-339.
Crossref
Crossref
W. Sullivan, M. Hirst, S. Beard, D. Gladwell, F. Fagnani, J. López Bastida, C. Phillips & W. C. N. Dunlop. (2015) Economic evaluation in chronic pain: a systematic review and de novo flexible economic model. The European Journal of Health Economics 17:6, pages 755-770.
Crossref
Crossref
S. Tafelski, T. Beutlhauser, F. Bellin, E. Reuter, T. Fritzsche, C. West & M. Schäfer. (2015) Auftreten von Obstipation bei Patienten mit ambulanter OpioidtherapieIncidence of constipation in patients with outpatient opioid therapy. Der Schmerz 30:2, pages 158-165.
Crossref
Crossref
Escarlata López Ramírez, D. M. Muñoz Carmona, J. Contreras Martínez & A. de la Torre Luque. (2016) Tapentadol in the management of opioid-naïve patients with cancer pain. Revista de la Sociedad Española del Dolor 23.
Crossref
Crossref
Lourdes Ferreira Laso, Amanda López Picado, Fernando Antoñanzas Villar, Laura Lamata de la Orden, Mar Ceballos Garcia, Carolina Ibañez López, Lorena Pipaon Ruilope, Felix Lamata Hernandez, Cesar Valero Martinez, Felipe Aizpuru & Roberto Hernandez Chaves. (2015) Cost-Effectiveness Analysis of Levobupivacaine 0.5 %, a Local Anesthetic, Infusion in the Surgical Wound After Modified Radical Mastectomy. Clinical Drug Investigation 35:9, pages 575-582.
Crossref
Crossref
Felicity C. Veal & Gregory M. Peterson. (2015) Pain in the Frail or Elderly Patient: Does Tapentadol Have a Role?. Drugs & Aging 32:6, pages 419-426.
Crossref
Crossref
Deepika Thakur, Sara Dickerson, Mohit Kumar Bhutani & Rod Junor. (2015) Impact of Prolonged-release Oxycodone/Naloxone on Outcomes Affecting Patients' Daily Functioning in Comparison With Extended-release Tapentadol: A Systematic Review. Clinical Therapeutics 37:1, pages 212-224.
Crossref
Crossref